 "Caplin Point Lab surges 15% on strong Q4 results")
Caplin Point Laboratories surged 15% to Rs 467, also its 52-week high, on BSE in early morning trade after the company more than doubled its consolidated net profit at Rs 33 crore in March quarter (Q4FY17), on the back of strong revenue growth. The pharmaceutical company had reported profit of Rs 16 crore in the same quarter a year ago.
Gross revenues during the quarter under review increased by 47% to Rs 121 crore against Rs 82 crore in the corresponding quarter of previous fiscal.
Earnings before interest, tax, depreciation and amortization (EBITDA) margin improved to 40% from 27% in Q4FY16.
The company said it has received the US Food and Drug Administration (US FDA) approval for injectable site at Chennai (CP-4).
The board has recommended a Dividend of 75% (i.e) Rs 1.50 paise per equity share at the face value of Rs 2 each for the financial year ended March 31, 2017.
At 09:29 am; the stock was up 9% at Rs 443 on BSE as compared to 0.22% rise in the S&P BSE Sensex. The trading volumes on the counter more than doubled with a combined 303,446 shares changed hands on the BSE and NSE so far.
Gross revenues during the quarter under review increased by 47% to Rs 121 crore against Rs 82 crore in the corresponding quarter of previous fiscal.
Earnings before interest, tax, depreciation and amortization (EBITDA) margin improved to 40% from 27% in Q4FY16.
The company said it has received the US Food and Drug Administration (US FDA) approval for injectable site at Chennai (CP-4).
The board has recommended a Dividend of 75% (i.e) Rs 1.50 paise per equity share at the face value of Rs 2 each for the financial year ended March 31, 2017.
At 09:29 am; the stock was up 9% at Rs 443 on BSE as compared to 0.22% rise in the S&P BSE Sensex. The trading volumes on the counter more than doubled with a combined 303,446 shares changed hands on the BSE and NSE so far.
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%